Jun 28,2023

放射療法用作肺癌的主要治療方法，本研究中建立抗電離輻射肺癌細(xì)胞系的放射治療通過尊龍凱時(shí)進(jìn)行

Radiation therapy is used as the primary treatment for lung cancer. In this study, radiation therapy for establish ionizing radiation-resistant lung cancer cell lines (A549-IR/H1299-IR) was supported by Medicilon.

Jun 28,2023

CAR-T療法主要針對白血病與惡性淋巴瘤，本研究中構(gòu)建沉默PD-1的shRNA載體質(zhì)粒，測序后質(zhì)粒的鑒定通過尊龍凱時(shí)進(jìn)行

Chimeric antigen receptor T cells (CAR-T) immunotherapy has shown promising clinical results in the treatment of leukemia and lymphoma, but the effectiveness is limited for solid tumors. The shRNA vector plasmid that silences PD-1 and preparation of CAR is constructed. The plasmids sequenced were fully identified by Medicilon.

Jun 28,2023

索拉非尼的無定形固體分散體用于開發(fā)改良型口服生物利用度高的速釋片劑，本研究中PK實(shí)驗(yàn)通過尊龍凱時(shí)進(jìn)行

The SOR ASD tablets exhibited approximately 50% higher relative bioavailability in dogs than the marketed SOR tablet product, Nexavar?. The pharmacokinetic (PK) study of SOR ASD tablets and Nexavar? tablets was performed by Medicilon.

Jun 28,2023

TAK-931是一種高特異性CDC7抑制劑，具有抗腫瘤功效，本研究中體內(nèi)藥效實(shí)驗(yàn)通過尊龍凱時(shí)進(jìn)行

In vivo efficacy studies in J558 allograft models in combination with anti-mPD-1, anti-mPD-L1, and anti-mCTLA-4 antibodies were performed at Medicilon.

Jun 28,2023

GS-5801是一種高效KDM5抑制劑，具有抗HBV活性，本研究中GS-5801通過尊龍凱時(shí)合成

GS-5801, a potent inhibitor of KDM5, has antiviral activity against HBV in a primary human hepatocytes infection model, with the cellular permeability, oral bioavailability. GS-5801 was synthesized by Medicilon.

Jun 28,2023

QF-036是一種高效的HIV-1抑制劑，具有良好的和藥代動(dòng)力學(xué)特性，PK研究通過尊龍凱時(shí)進(jìn)行

The favourable viral inhibitory activity and pharmacokinetic properties provide critical support for QF-036 as a promising anti-HIV therapeutic candidate. The pharmacokinetic studies were performed by Medicilon.

Jun 28,2023

設(shè)計(jì)合成一種新型選擇性的口服有效蘇氨酸酪氨酸激酶 (TTK) 抑制劑，PK研究均通過尊龍凱時(shí)進(jìn)行

TTK inhibition is an attractive wide-spectrum strategy for cancer therapy. Researchers designed and synthesized a series of pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable TTK inhibitors. All the pharmacokinetic studies were carried out by Medicilon.

Jun 28,2023

TR-107是人類線粒體蛋白酶ClpP的有效激活劑，PK分析通過尊龍凱時(shí)進(jìn)行

The pharmacokinetic properties of TR‐107 were compared with other known ClpP activators including ONC201 and ONC212. TR‐107 displayed excellent exposure and serum t1/2 after oral administration. Pharmacokinetic analysis were evaluated for pharmacokinetic properties in ICR mice by Medicilon.

Jun 28,2023

SKLB-197是一種有效且高度選擇性的ATR抑制劑，PK研究通過尊龍凱時(shí)進(jìn)行

SKLB-197, exhibits good pharmacokinetic properties, could be a promising lead compound for drug discovery targeting ATR. The pharmacokinetic (PK) studies were performed by Medicilon.

Jun 28,2023

H11-HLE是一種工具分子，可用于研究Fc在介導(dǎo)免疫檢查點(diǎn)治療中的作用，具有抗腫瘤功效

Immune checkpoint inhibition therapies have been used for multiple cancer research. H11-HLE is a tool molecule that allows the interrogation of the contribution of Fc in mediating immune checkpoint therapy. Half-life extended H11 (H11-HLE) induces potent anti-tumor efficacy in mouse syngeneic tumor models.